DCM
VTGN icon

DAFNA Capital Management’s VistaGen Therapeutics VTGN Stock Holding History

DAFNA Capital Management’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-41,886
Closed -$215K – 81
2023
Q4 		$215K Buy
+41,886
New +$159K 0.05% 70
2016
Q3 		– Sell
-1,563
Closed -$183K – 92
2016
Q2 		$183K Buy
+1,563
New +$179K 0.15% 81

Other funds holding VTGN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

DAFNA Capital Management's VTGN Position: Q1 2024 in Review

DAFNA Capital Management sold out of VistaGen Therapeutics (VTGN) in Q1 2024, closing a stake of 41,886 shares — an estimated $215K sold.

DAFNA Capital Management first reported a position in VTGN in Q2 2016 and held it in 2 quarters. The position peaked at $215K in Q4 2023. 42 funds tracked by Wall St. Rank hold VTGN as of Q1 2024.

  • DAFNA Capital Management reported no remaining VistaGen Therapeutics position as of Q1 2024 after selling out during the quarter.
  • DAFNA Capital Management sold 41,886 VistaGen Therapeutics shares in Q1 2024, an estimated $215K.
  • DAFNA Capital Management first reported a position in VistaGen Therapeutics in Q2 2016 and held it in 2 quarters.
  • DAFNA Capital Management's VistaGen Therapeutics position peaked at $215K in Q4 2023.
  • 42 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2024.

Based on DAFNA Capital Management's 13F filing for Q1 2024, filed 15 May 2024.